---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-071321"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2024-03-19T23:59:59+00:00"
generated_at: "2026-06-04T13:39:13.536710+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Taysha reports 2023 net loss of $111.6M; TSHA-102 shows sustained improvements in Rett patients

## Summary
- Revenue of $15.5M for full-year 2023 (up from $2.5M in 2022) from Astellas option agreement.
- Net loss of $111.6M ($0.96 loss per basic share) vs. $166.0M ($3.78/share) in 2022; includes $34.5M non-cash warrant expense.
- Cash and equivalents of $143.9M as of Dec 31, 2023; cash runway expected into 2026.
- TSHA-102 low dose (5.7x10^14 vg) in REVEAL adult trial: well-tolerated, no SAEs; patient 1 shows improved sitting, sleep, social interaction at week 35; patient 2 shows reduced seizures at week 19.
- IDMC approved early dose escalation to high dose (1x10^15 vg) in adult/pediatric trials; initial pediatric low-dose data due mid-2024.

## SEC filing metadata
- accession: 0001193125-24-071321
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2024-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312524071321/0001193125-24-071321-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312524071321/d790281d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-071321
- JSON: https://secwatch.observer/filing/0001193125-24-071321.json
- Plain text: https://secwatch.observer/filing/0001193125-24-071321.txt

## Key facts
- Earnings Releases
  Taysha Gene Therapies, Inc. reported financial results for Full Year 2023.
  - Period: Full Year 2023
  - Result: reported results
  source text: On March 19, 2024, Taysha Gene Therapies, Inc. (the " Company ") reported financial results for the year ended December 31, 2023 and recent business and clinical updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312524071321/0001193125-24-071321-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.